Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

医学 内科学 临床终点 易普利姆玛 肿瘤科 癌症 胃肠病学 临床试验 免疫疗法
作者
Robert Hans Ingemar Andtbacka,Merrick I. Ross,Sanjiv S. Agarwala,Matthew H. Taylor,John T. Vetto,Rogerio I. Neves,Adil Daud,Hung T. Khong,Richard S. Ungerleider,Maki Tanaka,Kenneth F. Grossmann
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15_suppl): 9510-9510 被引量:47
标识
DOI:10.1200/jco.2017.35.15_suppl.9510
摘要

9510 Background: HF10 is a bioselected replication-competent oncolytic virus derived from HSV-1. Herein, we report the safety and efficacy data of HF10 + ipilimumab (ipi) combination treatment in a Phase II trial in melanoma. Methods: Key entry criteria: age ≥ 18 yrs, ECOG ≤ 2, Stage IIIB, IIIC, or IV unresectable melanoma, ipi naïve (IV administration) and measurable non-visceral lesion(s) suitable for injection. HF10 injected into single or multiple tumors (1 x 10 7 TCID 50 /mL/dose, up to 5mL depending on tumor size and number); 4 injections q1wk; then up to 15 injections q3wk. Four ipi IV infusions (3 mg/kg; concurrent with HF10) were administered q3wk. AEs assessed per CTCAE 4.0. Tumor responses were assessed per mWHO and irRC at 12, 18, 24, 36 and 48 wks for patients (pts) continuing on HF10 monotherapy. Primary endpoint was Best Overall Response Rate (BORR) at 24 wks. Dose limiting toxicity (DLT) defined as ≥ G3 non-hematologic/hematologic toxicity, ≥ G2 neurologic toxicity, or allergic event occurring within 1 st 3wks of therapy. Results: Of 46 pts enrolled and treated: 59% men, median age 67 yrs (range 28 to 91); disease stage 20% IIIB, 43% IIIC and 37% IV; 57% were treatment naïve and 43% with ≥ 1 prior cancer therapy for unresectable/metastatic melanoma. Most HF10-related AEs were ≤G2, similar to HF10 monotherapy. No DLTs were reported. 37% had ≥G3 AEs, the majority due to ipi. HF10-related ≥G3 AEs (n=3) were embolism, lymphedema, diarrhea, hypoglycemia, and groin pain. Of the 44 efficacy evaluable pts per irRC, BORR at 24 weeks was 41% (16% irCR and 25% irPR); disease stability rate was 68% (16% irCR, 25% irPR and 27% irSD). As of Feb 06, 2017, median PFS was 19 months and median overall survival was 21.8 months. Conclusions: The combination HF10 and ipilimumab treatment demonstrated a favorable benefit/risk profile and encouraging antitumor activity in pts with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. Clinical trial information: NCT02272855.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可乐完成签到,获得积分10
4秒前
wdy111举报徐per爱豆求助涉嫌违规
4秒前
5秒前
6秒前
6秒前
漂亮白枫完成签到,获得积分10
7秒前
情怀应助why359采纳,获得10
7秒前
CodeCraft应助wsj采纳,获得10
7秒前
7秒前
领导范儿应助DoctorDiDi采纳,获得10
7秒前
LaTeXer应助勤恳白山采纳,获得80
7秒前
10秒前
小爪冰凉发布了新的文献求助30
10秒前
11秒前
漂亮白枫发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
优雅灵波发布了新的文献求助10
13秒前
kong完成签到,获得积分10
14秒前
14秒前
JJ发布了新的文献求助10
14秒前
幸福大白发布了新的文献求助10
15秒前
16秒前
16秒前
123完成签到,获得积分10
16秒前
Qing完成签到,获得积分10
17秒前
小二郎应助搞笑5次采纳,获得10
17秒前
ZONG发布了新的文献求助20
19秒前
yyyyyyy发布了新的文献求助10
20秒前
勤奋幻柏发布了新的文献求助10
20秒前
why359发布了新的文献求助10
21秒前
21秒前
22秒前
23秒前
hahah完成签到,获得积分10
25秒前
伶俐绿柏发布了新的文献求助10
27秒前
狸宝的小果子完成签到 ,获得积分10
27秒前
汉堡包应助wzc采纳,获得10
27秒前
深情安青应助刀锋采纳,获得10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989450
求助须知:如何正确求助?哪些是违规求助? 3531621
关于积分的说明 11254315
捐赠科研通 3270207
什么是DOI,文献DOI怎么找? 1804928
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809176